$CBLI News
Last published 5y ago
- 5y agoCBLISTABCytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."PR NewswireFORT COLLINS, Colo., Aug. 31, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corpora
- 5y agoCBLICytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via WebcastPR NewswireFORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive of th
- 5y agoCBLICytocom, Inc. Reports Second Quarter 2021 Financial ResultsPR NewswireFORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported
- 5y agoCBLICytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance AgreementPR NewswireFORT COLLINS, Colo., Aug. 12, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to
- 5y agoCBLICytocom, Inc. to Report Second Quarter 2021 Financial ResultsPR NewswireFORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a
- 5y agoCBLICytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19PR NewswireFORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its port
- 5y agoCBLICytocom Inc. Provides Update on Completed Merger with Cleveland BioLabsPR NewswireFORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ:CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update rega
- 5y agoCBLICytocom, Inc. Receives Commitments for $90 Million in Equity and Debt FinancingPR NewswireFORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ:CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital. The f
- 5y agoCBLICleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed MergerPR NewswireFORT COLLINS, Colo. and BUFFALO, N.Y., July 6, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, today announced that the Company and Cytocom In
- 5y agoCBLICleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SECPR NewswireFORT COLLINS, Colo. and BUFFALO, N.Y., June 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, announced that its registration statement on SE
- 5y agoCBLIGenome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532ACCESS NewswireThe substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals
- 5y agoCBLICleveland BioLabs, Inc. Announces Closing of $14 Million Registered Direct Offering of Common StockACCESS NewswireCleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has closed its previously announced registered direct offering for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share.
- 5y agoCBLICleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common StockACCESS NewswireCleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the issuance and sale of 2,000,000 shares of its common stock at a purchase price of $7.00 per share in a registered direct offering. The closing of the offering is expected to occur on or about February 23, 2021, subject to the satis ...
- 5y agoCBLICleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.ACCESS NewswireCombined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions
- 5y agoCBLICleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.PR NewswireCleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a...
- 5y agoCBLICytocom to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During "J.P. Morgan Week 2021"PR NewswireCytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, announced today that the company is participating in...
- 5y agoCBLINew patent granted for: Methods and Compositions for the Treatment of Radiation-Related DisordersUS Patent Applications (USPTO)
- 6y agoCBLICEIXPNMGLIBAMoore Kuehn Encourages CBLI, CEIX, PNM, and GLIBA Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoCBLICytocom, Inc. Issues Shareholder LetterPR NewswireCytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, today announced that its Chief Executive Officer, Michael K....
- 6y agoCBLICytocom and Cleveland BioLabs Announce Definitive Merger AgreementPR NewswireCytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, and Cleveland BioLabs, Inc., (NASDAQ: CBLI), an...
- 6y agoCBLICytocom and Cleveland BioLabs Announce Definitive Merger AgreementACCESS NewswireMerger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions
- 6y agoCBLICleveland BioLabs Announces $3.175 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesACCESS NewswireCleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,515,878 shares of its common stock, at a purchase price of $2.0945 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Cleveland BioLabs has also agreed to issue to th ...
- 6y agoCBLICleveland BioLabs Reports First Quarter 2020 Financial Results and Development ProgressACCESS NewswireCleveland BioLabs, Inc. (NASDAQ:CBLI) today reported financial results and development progress for the first quarter ended March 31, 2020.